Related Experiment Videos
[Clinical study of aztreonam on respiratory tract infections caused by gram-negative pathogens]
Abstract:
Aztreonam (E-0734, AZT) was administered to pneumonia and chronic respiratory tract infections. The results were as follows: AZT was administered to 29 patients. Twenty-six cases were evaluable and 3 cases were excluded from evaluation of efficacy because 1 was Gram-positive infection, 2 were unclear symptom of infection. Pneumonia was 4 cases. Chronic respiratory tract infections were 22 cases. Clinical efficacy was judged as follows; excellent in 7 cases, good in 10 cases, fair in 5 cases and poor in 4 cases, then the efficacy rate was 65.4%. Efficacy rate in pneumonia, acute aggravation of diffuse panbronchiolitis and bronchiectasis with infection was 50%, 67% and 83%, respectively. Bacteriological response was judged on 21 cases with eradication rate was 66.7%. Bacteriological response classified by pathogen was as follows: All 6 isolates of H. influenzae, 2 in 6 isolates of P. aeruginosa, 4 in 5 isolates of H. parainfluenzae and all 3 isolates of K. pneumoniae were cleared. Total eradicated rate was 74.1%. Eruption was observed in 1 case as side effect. Abnormal laboratory findings were observed in 4 cases. Elevation of GOT and GPT was in 3 cases. Increase of eosinophil and basophil was in 1 case. AZT was considered to be a useful antibiotic for the treatment of respiratory tract infections, especially chronic respiratory tract infections, caused by Gram-negative pathogens.
Insights
Aztreonam (AZT) demonstrated a 65.4% clinical efficacy rate in treating respiratory tract infections, particularly effective against Gram-negative pathogens in chronic conditions. This antibiotic showed promise for managing complex bacterial respiratory infections.
Area of Science:
- Infectious Diseases
- Pharmacology
- Pulmonology
Background:
- Respiratory tract infections (RTIs) pose a significant clinical challenge.
- Gram-negative pathogens are common causative agents in RTIs, including pneumonia and chronic conditions.
- Effective antibiotic therapy is crucial for managing these infections and improving patient outcomes.
Purpose of the Study:
- To evaluate the clinical efficacy and bacteriological response of Aztreonam (AZT) in patients with pneumonia and chronic respiratory tract infections.
- To assess the safety profile of Aztreonam in this patient population.
- To determine the utility of Aztreonam for treating Gram-negative bacterial RTIs.
Main Methods:
- A clinical study involving 29 patients with RTIs was conducted.
- Twenty-six cases were evaluated for efficacy, with 4 cases of pneumonia and 22 of chronic RTIs.
- Clinical and bacteriological responses were assessed, along with adverse events and laboratory findings.
Main Results:
- Aztreonam achieved an overall clinical efficacy rate of 65.4%.
- Efficacy rates varied by condition: 50% for pneumonia, 67% for acute exacerbation of diffuse panbronchiolitis, and 83% for bronchiectasis with infection.
- A bacteriological eradication rate of 66.7% was observed, with notable success against H. influenzae and K. pneumoniae.
Conclusions:
- Aztreonam is considered a useful antibiotic for treating respiratory tract infections, especially chronic ones.
- The drug demonstrated particular effectiveness against Gram-negative pathogens commonly found in RTIs.
- Aztreonam exhibited a favorable safety profile with minimal side effects observed.